Johnson & Johnson Total Assets 2010-2022 | JNJ

Johnson & Johnson total assets from 2010 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Johnson & Johnson total assets for the quarter ending December 31, 2022 were $175.124B, a 2.29% decline year-over-year.
  • Johnson & Johnson total assets for 2021 were $182.018B, a 4.07% increase from 2020.
  • Johnson & Johnson total assets for 2020 were $174.894B, a 10.88% increase from 2019.
  • Johnson & Johnson total assets for 2019 were $157.728B, a 3.12% increase from 2018.
Johnson & Johnson Annual Total Assets
(Millions of US $)
2021 $182,018
2020 $174,894
2019 $157,728
2018 $152,954
2017 $157,303
2016 $141,208
2015 $133,411
2014 $130,358
2013 $132,683
2012 $121,347
2011 $113,644
2010 $102,908
2009 $94,682
Johnson & Johnson Quarterly Total Assets
(Millions of US $)
2022-09-30 $175,124
2022-06-30 $177,724
2022-03-31 $178,355
2021-12-31 $182,018
2021-09-30 $179,228
2021-06-30 $176,440
2021-03-31 $172,557
2020-12-31 $174,894
2020-09-30 $170,693
2020-06-30 $158,380
2020-03-31 $155,017
2019-12-31 $157,728
2019-09-30 $155,521
2019-06-30 $155,117
2019-03-31 $150,027
2018-12-31 $152,954
2018-09-30 $155,703
2018-06-30 $155,365
2018-03-31 $156,625
2017-12-31 $157,303
2017-09-30 $155,658
2017-06-30 $152,807
2017-03-31 $144,918
2016-12-31 $141,208
2016-09-30 $140,369
2016-06-30 $139,814
2016-03-31 $136,231
2015-12-31 $133,411
2015-09-30 $133,266
2015-06-30 $132,036
2015-03-31 $128,590
2014-12-31 $130,358
2014-09-30 $132,097
2014-06-30 $135,200
2014-03-31 $133,330
2013-12-31 $132,683
2013-09-30 $126,933
2013-06-30 $124,325
2013-03-31 $121,536
2012-12-31 $121,347
2012-09-30 $118,951
2012-06-30 $115,750
2012-03-31 $116,194
2011-12-31 $113,644
2011-09-30 $111,821
2011-06-30 $112,114
2011-03-31 $108,150
2010-12-31 $102,908
2010-09-30 $98,247
2010-06-30 $92,300
2010-03-31 $93,441
2009-12-31 $94,682
2009-09-30 $91,558
2009-06-30 $87,438
2009-03-31 $86,100
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $423.546B $94.943B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $323.536B 40.83
Novo Nordisk (NVO) Denmark $314.688B 41.26
Merck (MRK) United States $268.980B 13.85
AbbVie (ABBV) United States $257.579B 10.68
Pfizer (PFE) United States $244.460B 6.68
Novartis AG (NVS) Switzerland $198.337B 14.94